trueffelpix-shutterstock-com
Trueffelpix / Shutterstock.com
21 January 2016AmericasKevin O’Connor

Patentability of diagnostics: reasons for optimism

Over the last five years, US courts have consistently declared patent claims covering diagnostics ineligible for protection. As in other fields, the vulnerability of such claims to eligibility challenges undermines confidence in the ability to protect intellectual property assets using the patent system. However, other avenues of protection (eg, trade secrets) for diagnostic tests may be limited in view of commercialisation and/or regulatory requirements. Innovative companies should glean guidance from these cases and continue to pursue patent protection for their diagnostic tests.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
17 June 2026   A cancer diagnostics company has lost its bid to overturn a jury verdict in a major patent dispute that has also spawned parallel proceedings before the Federal Circuit and PTAB.
Americas
15 June 2026   Unanimous jury finds willful infringement, with the possibility of a trebled award and a much larger feud still to come.
Americas
12 June 2026   In a strong response to BioNTech, Moderna argues its next-gen vaccine is built on a fundamentally different design from the German biotech’s—setting up a scrap over whether a key patent should have been granted.